schliessen

Filtern

 

Bibliotheken

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.

The emergence of viable therapeutic strategies in metastatic renal cell carcinoma has invigorated translational and clinical research in this disease. Building upon the clinical activity observed with inhibition of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pa... Full description

Journal Title: Clinical cancer research : an official journal of the American Association for Cancer Research March 1, 2010, Vol.16(5), pp.1348-1354
Main Author: Rini, Brian I
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1078-0432 ; DOI: 10.1158/1078-0432.CCR-09-2273
Link: http://search.proquest.com/docview/733543845/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest733543845
title: New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
format: Article
creator:
  • Rini, Brian I
subjects:
  • Animals–Therapeutic Use
  • Antineoplastic Agents–Drug Therapy
  • Carcinoma, Renal Cell–Genetics
  • Clinical Trials As Topic–Drug Therapy
  • Humans–Genetics
  • Kidney Neoplasms–Genetics
  • Translational Medical Research–Genetics
  • Antineoplastic Agents
ispartof: Clinical cancer research : an official journal of the American Association for Cancer Research, March 1, 2010, Vol.16(5), pp.1348-1354
description: The emergence of viable therapeutic strategies in metastatic renal cell carcinoma has invigorated translational and clinical research in this disease. Building upon the clinical activity observed with inhibition of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, novel strategies are being investigated to extend existing clinical benefits. Preclinical study has identified potential molecular mechanisms of response and resistance, providing a rational basis for biomarker development as well as sequential and combination therapy strategies. Several treatment strategies have emerged that are in the early phases of clinical testing. Further clinical and translational research is needed to validate initial hypotheses and translate observations into novel treatment strategies.
language: eng
source:
identifier: ISSN: 1078-0432 ; DOI: 10.1158/1078-0432.CCR-09-2273
fulltext: fulltext
issn:
  • 10780432
  • 1078-0432
url: Link


@attributes
ID263917231
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid733543845
sourceidproquest
recordidTN_proquest733543845
sourcesystemPC
pqid733543845
display
typearticle
titleNew strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
creatorRini, Brian I
contributorRini, Brian I (correspondence author) ; Rini, Brian I (record owner)
ispartofClinical cancer research : an official journal of the American Association for Cancer Research, March 1, 2010, Vol.16(5), pp.1348-1354
identifierISSN: 1078-0432 ; DOI: 10.1158/1078-0432.CCR-09-2273
subjectAnimals–Therapeutic Use ; Antineoplastic Agents–Drug Therapy ; Carcinoma, Renal Cell–Genetics ; Clinical Trials As Topic–Drug Therapy ; Humans–Genetics ; Kidney Neoplasms–Genetics ; Translational Medical Research–Genetics ; Antineoplastic Agents
languageeng
source
descriptionThe emergence of viable therapeutic strategies in metastatic renal cell carcinoma has invigorated translational and clinical research in this disease. Building upon the clinical activity observed with inhibition of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, novel strategies are being investigated to extend existing clinical benefits. Preclinical study has identified potential molecular mechanisms of response and resistance, providing a rational basis for biomarker development as well as sequential and combination therapy strategies. Several treatment strategies have emerged that are in the early phases of clinical testing. Further clinical and translational research is needed to validate initial hypotheses and translate observations into novel treatment strategies.
version3
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/733543845/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontribRini, Brian I
titleNew strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
subject
0Animals–Therapeutic Use
1Antineoplastic Agents–Drug Therapy
2Carcinoma, Renal Cell–Genetics
3Clinical Trials As Topic–Drug Therapy
4Humans–Genetics
5Kidney Neoplasms–Genetics
6Translational Medical Research–Genetics
7Antineoplastic Agents
general
0English
110.1158/1078-0432.CCR-09-2273
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest733543845
issn
010780432
11078-0432
rsrctypearticle
creationdate2010
addtitleClinical cancer research : an official journal of the American Association for Cancer Research
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorRini, Brian I
startdate20100301
enddate20100301
citationpf 1348 pt 1354 vol 16 issue 5
lsr30VSR-Enriched:[eissn, description, pqid]
sort
titleNew strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
authorRini, Brian I
creationdate20100301
lso0120100301
facets
frbrgroupid6241890535780641567
frbrtype5
newrecords20181218
languageeng
creationdate2010
topic
0Animals–Therapeutic Use
1Antineoplastic Agents–Drug Therapy
2Carcinoma, Renal Cell–Genetics
3Clinical Trials As Topic–Drug Therapy
4Humans–Genetics
5Kidney Neoplasms–Genetics
6Translational Medical Research–Genetics
7Antineoplastic Agents
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontribRini, Brian I
jtitleClinical cancer research : an official journal of the American Association for Cancer Research
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulastRini
aufirstBrian I
auRini, Brian I
addauRini, Brian I
atitleNew strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance.
jtitleClinical cancer research : an official journal of the American Association for Cancer Research
risdate20100301
volume16
issue5
spage1348
epage1354
pages1348-1354
issn1078-0432
formatjournal
genrearticle
ristypeJOUR
doi10.1158/1078-0432.CCR-09-2273
urlhttp://search.proquest.com/docview/733543845/
eissn15573265
date2010-03-01